Skip to main content
SpringerLink
Log in

HER3

  • Living reference work entry
  • First Online:
Cancer Therapeutic Targets

  • 262 Accesses

Abstract

ErbB3/HER3 belongs to the family of ErbB receptors, which comprises  four transmembrane receptors that can bind more than ten different ligands. The ErbB3 receptor forms heterodimers with the other ErbB receptor family members, which is the necessary step to activate downstream prosurvival signaling. While ErbB3 signaling plays an important role in embryonic development, it has also been implicated in the development of cancer and in mediating resistance to anti-cancer treatments. In this chapter, we  summarize the state of anti-ErbB3 therapies currently in clinical development including the emerging clinical data on HRG mRNA as a potential prognostic and predictive biomarker.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, … Kraus MH. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995;10(9):1813–21. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7538656

  • Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res. 2003;1(3):165–75.

    CAS  PubMed  Google Scholar 

  • Aurisicchio L, Marra E, Roscilli G, Mancini R, Ciliberto G. The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget. 2012;3(8):744–58. doi:10.1074/jbc.M503833200.

    Article  PubMed  PubMed Central  Google Scholar 

  • Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, … Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci U S A. 2012;109(1):221–6. doi:10.1073/pnas.1115802109.

    Google Scholar 

  • Berghoff AS, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, … Birner P. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. Breast. 2014;23(5):637–43. doi:10.1016/j.breast.2014.06.011.

    Google Scholar 

  • Bezler M, Hengstler JG, Ullrich A. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol. 2012;6(5):516–29. doi:10.1016/j.molonc.2012.07.001>.

    Article  CAS  PubMed  Google Scholar 

  • Breuleux M. Role of heregulin in human cancer. Cell Mol Life Sci. 2007;64(18):2358–77. doi:10.1007/s00018-007-7120-0.

    Article  CAS  PubMed  Google Scholar 

  • Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol. 2007;190:1–65.

    Google Scholar 

  • Burden S, Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron. 1997;18:847–55. doi:10.1016/S0896-6273(00)80324-4.

    Article  CAS  PubMed  Google Scholar 

  • Casalini P, Iorio MV, Galmozzi E, Menard S. Role of HER receptors family in development and differentiation. J Cell Physiol. 2004;200(3):343–50. doi:10.1002/jcp.20007.

    Article  CAS  PubMed  Google Scholar 

  • Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, … Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19(1):58–71. doi:10.1016/j.ccr.2010.10.031.

    Google Scholar 

  • Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;284(1):54–65. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12648465

  • Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, … Arteaga CL. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res. 2011;71(18):3941–51. doi:10.1158/0008-5472.CAN-10-3775.

    Google Scholar 

  • Curley MD, Sabnis GJ, Wille L, Adiwijaya BS, Garcia G, Moyo V, … MacBeath G. Seribantumab, an anti-ERBB3 antibody, delays the onset of resistance and restores sensitivity to letrozole in an estrogen receptor-positive breast cancer model. Mol Cancer Ther. 2015;1–12. doi:10.1158/1535-7163.MCT-15-0169.

    Google Scholar 

  • Denlinger CS, Keedy VL, Cleary JM, Kubasek W, Onsum M, Moulis S, … Shapiro G. Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors. In: ASCO annual meeting abstracts. 2013. p. 2609.

    Google Scholar 

  • Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël M-J, Fartoux L, Venot C, Bladt F, … Rosmorduc O. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(17):5445–56. doi:10.1158/1078-0432.CCR-08-2980.

    Google Scholar 

  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, … Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–43. doi:10.1126/science.1141478.

    Google Scholar 

  • Erickson SL, O’Shea KS, Ghaboosi N, Loverro L, Frantz G, Bauer M, … Moore MW. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development. 1997;124(24):4999–5011.

    Google Scholar 

  • Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284(1):14–30. doi:10.1016/S0014-4827(02)00102-7.

    Article  CAS  PubMed  Google Scholar 

  • Fattore L, Marra E, Pisanu ME, Noto A, de Vitis C, Belleudi F, … Ciliberto G. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med. 2013;11(1):180. doi:10.1186/1479-5876-11-180.

    Google Scholar 

  • Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, … Lugovskoy Aa. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014;13(2):410–25. doi:10.1158/1535-7163.MCT-13-0255.

    Google Scholar 

  • Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, … Radinsky R. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther. 2009;8(6):1536–46. doi:10.1158/1535-7163.MCT-08-0978.

    Google Scholar 

  • Freeman DJ, Ogbagabriel S, Bready J, Sun J-R, Radinsky R, Hettmann T. Abstract A182: U3–1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu model of human squamous cell carcinoma of the head and neck (SCCHN). In: AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics. 2011.

    Google Scholar 

  • Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, … Ettenberg Sa. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013. doi:10.1158/0008-5472.CAN-13-1198.

    Google Scholar 

  • Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, … Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A. 2011;3(12):1–6. doi:10.1073/pnas.1016140108.

    Google Scholar 

  • Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg Sa, Collins SD, … Arteaga CL. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks pi3k signaling and growth of HER2+ breast cancers. Cancer Res. 2013;73(19):6013–23. doi:10.1158/0008-5472.CAN-13-1191.

    Google Scholar 

  • Geuijen C, Rovers E, Nijhuis R, Visser T, Blanken-smit R. Den, Bartelink W, … Merus BV. Preclinical activity of MCLA-128, an ADCC enhanced human bispecific IgG1 antibody targeting the HER2: HER3 heterodimer. J Clin Oncol 2014;32:5s, (p. 2011).

    Google Scholar 

  • Geuijen C, Rovers E, Gallenne T, Maussang-Detaille D, Kramer A, Nieuwenhuizen N, … Throsby, M. Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2:HER3 heterodimer. Cancer Res. 2015;75:LB-261. doi: 10.1158/1538-7445.AAM2015-LB-261.

    Google Scholar 

  • Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, … Sugihara K. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 2008;14(23):7843–9. doi:10.1158/1078-0432.CCR-08-1064.

    Google Scholar 

  • Hegde GV, de la Cruz CC, Chiu C, Alag N, Schaefer G, Crocker L, … Jackson EL. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med. 2013;5(171):171ra18. doi:10.1126/scitranslmed.3004438.

    Google Scholar 

  • Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, … Miller K. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. J Clin Oncol (Meeting Abstracts). 2014;32(No 15_suppl):587.

    Google Scholar 

  • Hill A, Findlay M, Burge M, Jackson C, Alfonso PG, Samuel L, … Tabernero J. Randomized phase II study of Duligotuzumab + FOLFIRI vs Cetuximab + FOLFIRI in 2nd-line Patients with KRAS wild-type metastatic colorectal cancer. In: AACR 106th annual meeting 2015; Philadelphia; 2015.

    Google Scholar 

  • Hirakawa T, Nakata B, Amano R, Kimura K, Shimizu S, Ohira G, … Hirakawa K. HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Oncology. 2011;81(3–4):192–8. doi:10.1159/000333825.

    Google Scholar 

  • Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100(15):8933–8. doi:10.1073/pnas.1537685100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, … Lewis GD. Identification of heregulin, a specific activator of p185erbB2. Science. 1992;256(5060):1205–10. doi:10.1126/science.256.5060.1205.

    Google Scholar 

  • Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, … Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010;70(3):1204–14. doi:10.1158/0008-5472.CAN-09-3321.

    Google Scholar 

  • Huang S-M, Li C, Armstrong Ea, Peet CR, Saker J, Amler LC, … Harari PM. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 2013;73(2):824–33. doi:10.1158/0008-5472.CAN-12-1611.

    Google Scholar 

  • Hutcheson IR, Goddard L, Barrow D, McClelland Ra, Francies HE, Knowlden JM, … Gee JM. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Res. 2011;13(2):R29. doi:10.1186/bcr2848.

    Google Scholar 

  • Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, … Gee JMW. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Res. 2011;13(2):R29. doi:10.1186/bcr2848.

    Google Scholar 

  • Isakoff SJ, Saleh MN, Lugovskoy A, Manoli S, Czibere AG, LoRusso P, Arnedos M. First-in-human study of MM-141: a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3. In J Clin Oncol. 2014;32:5s.

    Article  Google Scholar 

  • Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, … Seshagiri S. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23(5):603–17. doi:10.1016/j.ccr.2013.04.012.

    Google Scholar 

  • Jiang N, Wang D, Hu Z, Shin HJC, Qian G, Rahman MA, … Saba N. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of Head and Neck Squamous Cell Carcinoma (HNSCC). Mol Cancer Ther. 2014. doi:10.1158/1535-7163.MCT-13-1093.

    Google Scholar 

  • Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 2006;439(7073):168–74. doi:10.1038/nature04177.

    Article  CAS  PubMed  Google Scholar 

  • Kawakami H, Okamoto I, Yonesaka K, Okamoto K. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014;5(23):11847–56.

    Google Scholar 

  • Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, … Onsum MD. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal. 2013;6(288):ra68. doi:10.1126/scisignal.2004008.

    Google Scholar 

  • Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, … Lutterbach B. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008. doi:10.1158/0008-5472.CAN-07-5229.

    Google Scholar 

  • Lee D, Yu M, Lee E, Kim H, Yang Y, Kim K, … Threadgill DW. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest. 2009;119(9):2702–13. doi:10.1172/JCI36435.

    Google Scholar 

  • Lemke GE, Brockes JP. Identification and purification of glial growth factor. J Neurosci. 1984;4(1):75–83.

    Google Scholar 

  • Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, … Pujade-Lauraine E. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. J Clin Oncol (Meeting Abstracts). 2014;32(No 15_suppl):5519.

    Google Scholar 

  • Lorusso PM, Janne Pa, Ribeiro de Oliveira M, Rizvi Na, Malburg L, Keedy VL, … Berlin J. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2013;19(11):986015. doi:10.1158/1078-0432.CCR-12-3051.

    Google Scholar 

  • Macbeath G, Adiwijaya B, Liu J, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, … Czibere A. A meta-analysis of biomarkers in three randomized, phase 2 studies of MM-121, a ligand-blocking anti-ErbB3 antibody, in patients with ovarian, lung and breast cancers. Ann Oncol. 2014; 25(Supplement 4):iv58–84.

    Google Scholar 

  • McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, … Nielsen UB. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther. 2012;11(3):582–93. doi:10.1158/1535-7163.MCT-11-0820.

    Google Scholar 

  • Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004;6:517–27. doi:10.1016/j.ccr.2004.09.031.

    Article  CAS  PubMed  Google Scholar 

  • Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, … Beckman RA. Clinical translation and validation of a predictive biomarker for patritumab, an anti-human epidermal growth factor receptor 3 (HER3) monoclonal antibody, in patients with advanced non-small cell lung cancer. EBioMed. 2015;2(3):264–71. doi:10.1016/j.ebiom.2015.02.005.

    Google Scholar 

  • Meneses-Lorente G, Friess T, Kolm I, Hölzlwimmer G, Bader S, Meille C, … Bossenmaier B. Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody. Cancer Chemother Pharmacol. 2015:837–50. doi:10.1007/s00280-015-2697-8.

    Google Scholar 

  • Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, … Cook RS. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. J Clin Invest. 2013;123(10):4329–43. doi:10.1172/JCI66764.

    Google Scholar 

  • Musgrove E a, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–43. doi:10.1038/nrc2713.

    Article  CAS  PubMed  Google Scholar 

  • Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst. 2013;105(4):266–73. doi:10.1093/jnci/djs501.

    Article  CAS  PubMed  Google Scholar 

  • Olayioye M a, Neve RM, Lane H a, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19(13):3159–67. doi:10.1093/emboj/19.13.3159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Onsum M, Yarar D, Paragas V, Zhang B, Stephanie N, Schoeberl B, … Nielsen U. Targeting ErbB3-addicted cancers across the HER2 spectrum. Cancer Res. 2012;72:4945. doi:10.1158/1538-7445.AM2012-4945.

    Google Scholar 

  • Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003;12(6):362–7. doi:10.1016/S0960-9776(03)00137-1.

    Article  PubMed  Google Scholar 

  • Papadopoulos KP, Adjei AA, Rasco DW, Liu L, Kao RJ, Brownstein CM, … Wang D. Phase 1 study of REGN1400 (anti-ErbB3) combined with erlotinib or cetuximab in patients (pts) with advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck cancer (SCCHN). J Clin Oncol (Meeting Abstracts). 2014;32(No 15_suppl):2516.

    Google Scholar 

  • Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 1993;12(3):961–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Penuel EV, Kapp A, Do A, Tam R, Sumiyoshi T, Marathe C, … Pirzkall A. Biomarker evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus cetuximab (Cet) in ≥2 line recurrent/metastatic (R/M) squamous cell carcinomas of the head and neck (SCCHN) [MEHGAN]. Cancer Res. 2015;75:1553 doi: 10.1158/1538-7445.AM2015-1553.

    Google Scholar 

  • Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, … Slamon DJ. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10(12):2435–46. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7784095

  • Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, … Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996;15(10):2452–67. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=450177&tool=pmcentrez&rendertype=abstract

  • Qian G, Jiang N, Wang D, Newman S, Kim S, Chen Z, … Saba NF. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. Cancer. 2015. doi:10.1002/cncr.29549.

    Google Scholar 

  • Richards L. Genetics: HER3 overexpression in breast cancer conveys a poor prognosis. Nat Rev Clin Oncol. 2010;7(8):423. doi:10.1038/nrclinonc.2010.106.

    Google Scholar 

  • Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, … Eigenbrot C. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell. 2011;20(4):472–86. doi:10.1016/j.ccr.2011.09.003.

    Google Scholar 

  • Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, … Nielsen UB. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal. 2009;2(77):ra31. doi:10.1126/scisignal.2000352.

    Google Scholar 

  • Schoeberl B, Faber AC, Li D, Liang M-C, Crosby K, Onsum M, … Wong K-K. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010a;70(6):2485–94. doi:10.1158/0008-5472.CAN-09-3145.

    Google Scholar 

  • Schoeberl B, Faber AC, Li D, Liang M-C, Crosby K, Onsum M, … Wong K-K. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010b;70(6):2485–94. doi:10.1158/0008-5472.CAN-09-3145.

    Google Scholar 

  • Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, … Shepherd FA. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. J Clin Oncol (Meeting Abstracts). 2014;32(No 15_suppl): 8051.

    Google Scholar 

  • Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445(7126):437–41. doi:10.1038/nature05474.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, … Amler. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS One. 2013;8(2):e56765. doi:10.1371/journal.pone.0056765.

    Google Scholar 

  • Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, … Liu JF. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010;17(3):298–310. doi:10.1016/j.ccr.2009.12.047.

    Google Scholar 

  • Soltoff SP, Carraway KL, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994;14(6):3550–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, … Hengstler JG. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006;24(26):4317–23. doi:10.1200/JCO.2005.04.8397.

    Google Scholar 

  • Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, … Scaltriti M. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 2014;7(318):ra29. doi:10.1126/scisignal.2005125.

    Google Scholar 

  • Telesco SE, Shih AJ, Jia F, Radhakrishnan R. A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network. Mol BioSyst. 2011;7(6):2066. doi:10.1039/c0mb00345j.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Traynor K. FDA approves pertuzumab for breast cancer. Am J Health Syst Pharm. 2012. doi:10.2146/news120049.

    Google Scholar 

  • Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, … Cook RS. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res. 2012;72(10):2672–82. doi:10.1158/0008-5472.CAN-11-3594.

    Google Scholar 

  • Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995;14(17):4267–75. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=394510&tool=pmcentrez&rendertype=abstract

  • Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, … Liu B. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res: BCR. 2013;15(5):R101. doi:10.1186/bcr3563.

    Google Scholar 

  • Yarar D, Lahdenranta J, Kubasek W, Nielsen UB, MacBeath G. Heregulin-ErbB3-driven tumor growth persists in PI3 kinase mutant cancer cells. Mol Cancer Ther. 2015;14(9):2072–80. doi:10.1158/1535-7163.MCT-15-0075.

    Article  CAS  PubMed  Google Scholar 

  • Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37. doi:10.1038/35052073.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Merrimack Pharmaceuticals, Inc., One Kendall Square, Cambridge, MA, 02139, USA

    Alexey Lugovskoy, Michael Curley, Johanna Lahdenranta, Ashish Kalra, Akos Czibere, Gavin MacBeath & Birgit Schoeberl

Authors
  1. Alexey Lugovskoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Curley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johanna Lahdenranta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ashish Kalra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akos Czibere
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gavin MacBeath
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Birgit Schoeberl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Birgit Schoeberl .

Editor information

Editors and Affiliations

  1. Georgetown University Div. Hematology & Oncology, Washington, District of Columbia, USA

    John L. Marshall

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this entry

Cite this entry

Lugovskoy, A. et al. (2015). HER3. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6613-0_95-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6613-0_95-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Online ISBN: 978-1-4614-6613-0

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation